Nicolette M Fonseca, Corinne Maurice-Dror, Cameron Herberts, Wilson Tu, William Fan, Andrew J Murtha, Catarina Kollmannsberger, Edmond M Kwan, Karan Parekh, Elena Schönlau, Cecily Q Bernales, Gráinne Donnellan, Sarah W S Ng, Takayuki Sumiyoshi, Joanna Vergidis, Krista Noonan, Daygen L Finch, Muhammad Zulfiqar, Stacy Miller, Sunil Parimi, Jean-Michel Lavoie, Edward Hardy, Maryam Soleimani, Lucia Nappi, Bernhard J Eigl, Christian Kollmannsberger, Sinja Taavitsainen, Matti Nykter, Sofie H Tolmeijer, Emmy Boerrigter, Niven Mehra, Nielka P van Erp, Bram De Laere, Johan Lindberg, Henrik Grönberg, Daniel J Khalaf, Matti Annala, Kim N Chi, Alexander W Wyatt
No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratification is unclear. Here, we intersect ctDNA%, treatment outcomes, and clinical characteristics across 738 plasma samples from 491 male mCRPC patients from two randomized multicentre phase II trials and a prospective province-wide blood biobanking program. ctDNA% correlates with serum and radiographic metrics of disease burden and is highest in patients with liver metastases...
February 28, 2024: Nature Communications